Stonegate Capital Partners Initiates Coverage on NU Skin Enterprises Inc. with Optimistic Outlook
Stonegate Capital Partners begins coverage on NU Skin Enterprises Inc., highlighting its strong quarterly performance, strategic initiatives, and positive future guidance.
Stonegate Capital Partners has initiated coverage on NU Skin Enterprises Inc. (NYSE: NUS), spotlighting the company's robust quarterly results and strategic growth initiatives. NU Skin reported revenue, adjusted net income, and adjusted EPS of $386.1 million, $21.1 million, and $0.43, respectively, with revenue at the high end of its guidance range. The Rhyz Manufacturing segment notably achieved a 17% year-over-year revenue growth, while EPS significantly outpaced guidance. A gross margin of 68.8% for the quarter, up from the previous quarter, underscores the company's operational efficiency and revenue growth focus.
NU Skin's strategic initiatives, including expansion into India and the launch of the Prysm iO wellness device, are poised to drive near to medium-term growth. The company's entry into the Indian market is scheduled for mid-2026, following pre-opening activities in late 2025. The Prysm iO, an AI-powered wellness assessment device, is expected to revolutionize personalized product recommendations, leveraging NU Skin's proprietary subscription service. These initiatives are anticipated to invigorate brand representatives and sales leaders, further fueling growth.
Despite a year-over-year decline in sales leaders, paid affiliates, and customers, NU Skin demonstrated strong revenue growth in Latin America, attributed to its scalable digital-first model. The company's solid balance sheet, with $264.2 million in cash and a positive net cash position, provides flexibility to execute its strategic initiatives. NU Skin has tightened its FY25 revenue guidance to $1.48 billion to $1.55 billion and raised its adjusted EPS guidance to $1.15 to $1.35, reflecting confidence in its operational and strategic direction.
Stonegate Capital Partners values NU Skin at a forward Price to Adjusted EPS of 5.2x, below the average comparison, applying a valuation range that suggests potential upside. With its strong performance, strategic initiatives, and positive guidance, NU Skin Enterprises Inc. is positioned for continued growth and success in the global market. For more information, visit https://www.nuskin.com.